Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

A Call for Caution in Prescribing Gabapentin to Individuals With Concurrent Polysubstance Abuse

A Case Report

MARTINEZ, GABRIEL M. DO; OLABISI, JENDAYI MD; RUEKERT, LAURA PharmD; HASAN, SYED MD

Journal of Psychiatric Practice®: July 2019 - Volume 25 - Issue 4 - p 308–312
doi: 10.1097/PRA.0000000000000403
Clinical Case Discussions
Buy

Gabapentin is an anticonvulsant medication with an indication from the US Food and Drug Administration for use in partial onset seizures and postherpetic neuralgia in the United States. Currently, gabapentin is only classified as a controlled substance subject to stricter prescribing and distributing regulations in certain states, as opposed to pregabalin, an anticonvulsant with a similar mechanism of action which is a considered a Schedule V medication under federal law. Gabapentin shares a structural similarity to pregabalin, and several case reports have suggested that gabapentin has a similar propensity for abuse. The mechanisms of the gabapentin reward pathway, addiction, and withdrawal, however, are not well known. This case report describes a patient with long-term polysubstance abuse and new onset gabapentin dependence and demonstrates the need for increased surveillance of gabapentin prescribing.

MARTINEZ, OLABISI, HASAN: Community Health Network, Indianapolis, IN

RUEKERT: Behavioral Care, Community Hospital North, Indianapolis, IN

The authors declare no conflicts of interest

Please send correspondence to: Gabriel M. Martinez, DO, Community Health Network, 7165 Clearvista Way, Indianapolis, IN 46256 (e-mail: gmartinez2@ecommunity.com).

Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.